P075 | DOLOMY FIBRO® IN THE TREATMENT OF OROFACIAL PAIN: CASE REPORT
A. Vercesi1, G. Bellantoni2, G. Arcuri3, L. Pucci4, E. Domina5, E. Pucci6 | 1Scientific Consultant Biosphaera Pharma; 2Head and Neck Department. Neurosurgery Unit. IRCCS Policlinico "S. Matteo". University of Pavia, Italy; 3Head of the Orthopedic Rehabilitation Complex Unit, "Città di Pavia" Clinical Institute, Italy; 4Master’s Degree in Dietetics and Clinical Nutrition. University of Pavia, Italy; 5Neurology Unit. Maggiore Hospital. Lodi, Italy; 6Department of Nervous System and Bahavioral Sciences, University of Pavia, Italy
Abstract
Background. The nasal and oral mucosa, the tongue, and the teeth are structures that can cause facial pain, as can dental treatments that lead to the onset of so-called "atypical" facial pain. The IHS classification establishes the diagnostic criteria in Chapter 13, dedicated to Cranial Neuralgia and Central Facial Pain.
Methods. A 67-year-old female patient presented with orofacial pain and right hemifacial edema following a right upper premolar avulsion due to a granuloma. Treatment with Dolomy FIBRO® 1+1 capsules/day was initiated to control the edema and orofacial pain, with neuralgic symptoms affecting the second branch of the right trigeminal nerve. The patient kept a diary of her clinical progress and, in particular, monitored her pain using a VAS (Visual Analogue Scale). Efficacy and tolerability data were also collected.
Results. The patient reported a reduction in edema after 7 days, with its elimination after 14 days of administration of Dolomy FIBRO® 1+1 capsules/day. Pain intensity in the first 14 days was significantly reduced (VAS: 8 at T0; VAS: 2 at T1 – 14 days). The patient continued therapy with Dolomy FIBRO® 1+1 capsules/day for another 60 days until the orofacial pain resolved.
Conclusions. As can be seen from the case report, Dolomy FIBRO® cps can be used to treat orofacial pain, especially in the presence of edema. Future research will explore the possibility of combining Dolomy FIBRO® cps with antiepileptic drug therapy, which is commonly used to treat typical and atypical neuralgia.
Methods. A 67-year-old female patient presented with orofacial pain and right hemifacial edema following a right upper premolar avulsion due to a granuloma. Treatment with Dolomy FIBRO® 1+1 capsules/day was initiated to control the edema and orofacial pain, with neuralgic symptoms affecting the second branch of the right trigeminal nerve. The patient kept a diary of her clinical progress and, in particular, monitored her pain using a VAS (Visual Analogue Scale). Efficacy and tolerability data were also collected.
Results. The patient reported a reduction in edema after 7 days, with its elimination after 14 days of administration of Dolomy FIBRO® 1+1 capsules/day. Pain intensity in the first 14 days was significantly reduced (VAS: 8 at T0; VAS: 2 at T1 – 14 days). The patient continued therapy with Dolomy FIBRO® 1+1 capsules/day for another 60 days until the orofacial pain resolved.
Conclusions. As can be seen from the case report, Dolomy FIBRO® cps can be used to treat orofacial pain, especially in the presence of edema. Future research will explore the possibility of combining Dolomy FIBRO® cps with antiepileptic drug therapy, which is commonly used to treat typical and atypical neuralgia.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.